Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 17, 2026Clinical Journal of the American Society of Nephrology

Validation of Urinary C-C Motif Chemokine Ligand 14 for Persistent Severe AKI Using Clinical Adjudication

View Full Paper
Ask AI
Bookmark
Share

Authors

JKJ. Patrick KampfAAAli Al-KhafajiSASwati Arora

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kampf et al. (2026) studied this question.

synapsesocial.com/papers/6aabb8375f706d05830e7dcchttps://doi.org/10.2215/cjn.0000001212
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Performance of a Standardized Clinical Assay for Urinary C–C Motif Chemokine Ligand 14 (CCL14) for Persistent Severe Acute Kidney Injury2022 · 61 citations
  2. 2Assessing the role of Chemokine (C–C motif) ligand 14 in AKI: a European consensus meeting2024 · 4 citations
  3. 3Assessment of urine CCL2 as a potential diagnostic biomarker for acute kidney injury and septic acute kidney injury in intensive care unit patients2024 · 3 citations
  4. 445: LEVERAGING URINE BIOMARKERS TO PREDICT ACUTE KIDNEY INJURY IN CRITICALLY ILL CHILDREN2026
  5. 5Predictive performance of two types of urinary biomarkers for renal non-recovery in sepsis-associated acute kidney injury: a prospective observational study2024